Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.67
+$0.04 · +0.86%
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Previous close
$4.67
+$0.04 · +0.86%
Regular session · ET · Market data may be delayed.
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Day range
Current $4.67
52-week range
Current $4.67
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
70
Undervalued
Sentiment
61
Bullish
Risk
85
Extreme Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Day range
Current $4.67
52-week range
Current $4.67
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.98M USD | 2.5M USD | 2.54M USD | 1.71M USD | 1.16M USD |
| Gross profit | 2.98M USD | 2.5M USD | 2.54M USD | 1.71M USD | 1.16M USD |
| Research and development | 3.07M USD | 3.29M USD | 3.49M USD | 4.77M USD | 3.16M USD |
| Selling, general, and administrative | 2.75M USD | 3.42M USD | 3.56M USD | 3.65M USD | 3.74M USD |
| Operating expenses | 5.81M USD | 6.7M USD | 7.06M USD | 8.42M USD | 6.91M USD |
| Interest income | 148K USD | 249.86K USD | 355.76K USD | 167.15K USD | 100.47K USD |
| Depreciation and amortization | — | 153.34K USD | — | 27.04K USD | 35.48K USD |
| Operating income | −2.83M USD | −4.2M USD | −4.52M USD | −6.72M USD | −5.75M USD |
| Net income | −2.68M USD | −3.96M USD | −4.13M USD | −6.55M USD | −5.65M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 15, 2023 | 1:10 | — | — |
Stock split | Jun 25, 2019 | 1:12 | — | — |
Stock split | Jun 6, 2016 | 1:33 | — | — |
Effective May 15, 2023
1:10
Effective Jun 25, 2019
1:12
Effective Jun 6, 2016
1:33
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
